For US residents only.
The Know Now BRAF Testing Program has concluded, effective April 30, 2022. Novartis remains committed to expanding awareness of BRAF testing. For additional information on melanoma and BRAF mutations, please visit our site.
Copyright © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.